Table 2.
Healthcare resource utilization measured per patient per month among patients with metastatic non-small-cell lung cancer epidermal growth factor receptor activating mutation with and without disease progression within 12 months after first-line initiation on an epidermal growth factor receptor activating tyrosine kinase inhibitor.
| No disease progression in the first 12 months | With disease progression in the first 12 months | p-value (w/progression vs no progression) | Disease progression in months 0–6 | p-value (w/progression in months 0–6 vs no progression) | Disease progression in months 7–12 | p-value (w/progression in months 7–12 vs no progression) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 127 | n = 101 | n = 46 | n = 55 | ||||||||
| Inpatient | |||||||||||
| Patients with ≥1 admission: n, % | 23 | 18.1% | 55 | 54.5% | 0.000 | 24 | 52.2% | 0.000 | 31 | 56.4% | 0.000 |
| Number of admissions, PPPM: mean, SD | 0.03 | 0.07 | 0.11 | 0.14 | 0.000 | 0.13 | 0.16 | 0.000 | 0.09 | 0.11 | 0.000 |
| Length of stay (in days) per admission: mean, SD | 0.08 | 0.21 | 0.40 | 0.68 | 0.000 | 0.53 | 0.87 | 0.000 | 0.30 | 0.45 | 0.000 |
| Outpatient | |||||||||||
| Emergency room visitis | |||||||||||
| Patients with ≥1 emergency room visit: n, % | 41 | 32.3% | 62 | 61.4% | 0.000 | 25 | 54.3% | 0.008 | 37 | 67.3% | 0.000 |
| Number of emergency room visits, PPPM: mean, SD | 0.04 | 0.08 | 0.13 | 0.17 | 0.000 | 0.16 | 0.22 | 0.000 | 0.11 | 0.12 | 0.000 |
| Office-administered antineoplastics | |||||||||||
| Patients with ≥1 administration: n, % | 0 | 0.0% | 31 | 30.7% | 0.000 | 12 | 26.1% | 0.000 | 19 | 34.5% | 0.000 |
| Number of administrations, PPPM: mean, SD | 0.00 | 0.00 | 0.18 | 0.37 | 0.000 | 0.19 | 0.44 | 0.000 | 0.17 | 0.31 | 0.000 |
| Outpatient office visits | |||||||||||
| Patients with ≥1 office visit: n, % | 126 | 99.2% | 98 | 97.0% | 0.324 | 43 | 93.5% | 0.058 | 55 | 100.0% | 1.000 |
| Number of office visits, PPPM: mean, SD | 1.87 | 1.08 | 1.90 | 1.08 | 0.844 | 1.80 | 1.13 | 0.712 | 1.98 | 1.04 | 0.523 |
| Outpatient radiology | |||||||||||
| Patients with ≥1 radiology service: n, % | 125 | 98.4% | 98 | 97.0% | 0.657 | 44 | 95.7% | 0.288 | 54 | 98.2% | 1.000 |
| Number of radiology services, PPPM: mean, SD | 2.01 | 2.57 | 3.09 | 2.90 | 0.003 | 3.61 | 3.69 | 0.002 | 2.66 | 1.96 | 0.098 |
| Outpatient laboratory services | |||||||||||
| Patients with ≥1 laboratory service: n, % | 123 | 96.9% | 94 | 93.1% | 0.222 | 40 | 87.0% | 0.023 | 54 | 98.2% | 1.000 |
| Number of laboratory services, PPPM: mean, SD | 3.74 | 3.32 | 3.66 | 2.91 | 0.860 | 2.88 | 2.53 | 0.111 | 4.32 | 3.06 | 0.265 |
| Other outpatient services† | |||||||||||
| Patients with ≥1 other outpatient service: n, % | 125 | 98.4% | 101 | 100.0% | 0.504 | 46 | 100.0% | 1.000 | 55 | 100.0% | 1.000 |
| Number of other outpatient services, PPPM: mean, SD | 2.30 | 1.72 | 3.66 | 3.54 | 0.000 | 3.65 | 3.57 | 0.001 | 3.67 | 3.55 | 0.001 |
| Outpatient pharmacy | |||||||||||
| Patients with a ≥1 prescription (any): n, % | 127 | 100.0% | 101 | 100.0% | 1.000 | 46 | 100.0% | 1.000 | 55 | 100.0% | 1.000 |
| Number of prescriptions, PPPM: mean, SD | 4.15 | 2.31 | 3.93 | 1.91 | 0.448 | 4.07 | 1.93 | 0.827 | 3.82 | 1.90 | 0.355 |
| Patients with ≥1 prescription (antineoplastics): n, % | 127 | 100.0% | 101 | 100.0% | 1.000 | 46 | 100.0% | 1.000 | 55 | 100.0% | 1.000 |
| Number of prescriptions, PPPM: mean, SD | 1.07 | 0.24 | 0.75 | 0.33 | 0.000 | 0.71 | 0.33 | 0.000 | 0.79 | 0.33 | 0.000 |
| Hospice Care | |||||||||||
| Patients with any hospice care: n, % | 38 | 37.6% | n/a | 21 | 45.7% | n/a | 17 | 30.9% | n/a | ||
| Patients with inpatient hospice care: n, % | 16 | 15.8% | n/a | 10 | 21.7% | n/a | 6 | 10.9% | n/a | ||
| Patients with outpatient hospice care: n, % | 29 | 28.7% | n/a | 16 | 34.8% | n/a | 13 | 23.6% | n/a | ||
†
Inclusive of all other outpatient services not reported out individually.
EGFRm: Epidermal growth factor receptor activating mutation; mNSCLC: Metastatic non-small-cell lung cancer; PPPM: Per patient per month; SD: Standard deviation; TKI: Tyrosine kinase inhibitor.
Bolded indicates p < 0.05.
n/a: Not applicable.